CD8A and hepatocellular carcinoma: In a mouse HCC model, in vitro experiments have shown that epithelial cells and immune cells release IL-33, which can preferentially expand CD8+ T cells and induce the activation of CD4+ and CD8+ T cells in the spleen and liver, leading to enhanced CTL cytotoxicity and exerting anti-tumor immune effects [111].